TCRT (Alaunos Therapeutics) Cyclically Adjusted Book per Share: $2.91 (As of Mar. 2026)


TCRT Alaunos Therapeutics Inc TCRT
28 GF Score
Price $2.08
GF Value $0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Cyclically Adjusted Book per Share?

Alaunos Therapeutics TCRT -4.37% 28 Cyclically Adjusted Book per Share is $2.91 as of Mar. 2026. GuruFocus rates TCRT with a GF Score™ of 28/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Alaunos Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $0.542. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.91 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Alaunos Therapeutics's average Cyclically Adjusted Book Growth Rate was -82.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -42.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -31.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -21.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Alaunos Therapeutics was 15.00% per year. The lowest was -42.90% per year. And the median was -17.80% per year.

As of today (2026-07-06), Alaunos Therapeutics's current stock price is $2.08. Alaunos Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $2.91. Alaunos Therapeutics's Cyclically Adjusted PB Ratio of today is 0.71.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Alaunos Therapeutics was 18.36. The lowest was 0.07. And the median was 6.15.


Alaunos Therapeutics  (NAS:TCRT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alaunos Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.08/2.91
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Alaunos Therapeutics was 18.36. The lowest was 0.07. And the median was 6.15.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Alaunos Therapeutics Cyclically Adjusted Book per Share Related Terms


Alaunos Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics Cyclically Adjusted Book per Share Chart

Alaunos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.99 31.54 27.70 21.38 5.86

Alaunos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.90 12.81 9.26 5.86 2.91

TCRT vs DRMA, MBIO, ELAB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Cyclically Adjusted PB Ratio falls into.


TCRT
28GF Score
Alaunos Therapeutics Inc TCRT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alaunos Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.542/330.2130*330.2130
=0.542

Current CPI (Mar. 2026) = 330.2130.

Alaunos Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -59.214 241.018 -81.128
201609 -73.367 241.428 -100.348
201612 -87.540 241.432 -119.731
201703 -107.478 243.801 -145.572
201706 -67.943 244.955 -91.591
201709 -84.350 246.819 -112.850
201712 -101.794 246.524 -136.351
201803 -129.767 249.554 -171.709
201806 -146.718 251.989 -192.263
201809 -164.820 252.439 -215.599
201812 79.669 251.233 104.715
201903 68.591 254.202 89.101
201906 57.244 256.143 73.797
201909 87.925 256.759 113.079
201912 78.391 256.974 100.733
202003 126.198 258.115 161.448
202006 114.355 257.797 146.478
202009 101.483 260.280 128.750
202012 86.640 260.474 109.837
202103 73.617 264.877 91.776
202106 61.434 271.696 74.665
202109 47.680 274.310 57.397
202112 40.289 278.802 47.718
202203 34.113 287.504 39.181
202206 27.883 296.311 31.073
202209 22.285 296.808 24.793
202212 24.052 296.797 26.760
202303 18.397 301.836 20.127
202306 13.498 305.109 14.609
202309 8.666 307.789 9.297
202312 3.939 306.746 4.240
202403 2.996 312.332 3.168
202406 2.355 314.175 2.475
202409 1.701 315.301 1.781
202412 1.289 315.605 1.349
202503 0.661 319.799 0.683
202506 1.764 322.561 1.806
202509 1.271 324.800 1.292
202512 0.917 324.054 0.934
202603 0.542 330.213 0.542

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $2.91 mean?
Alaunos Therapeutics (TCRT) has a Cyclically Adjusted Book per Share of $2.91 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Alaunos Therapeutics and its competitors.
Is Alaunos Therapeutics' Cyclically Adjusted Book per Share too high?
Alaunos Therapeutics' current Cyclically Adjusted Book per Share is $2.91. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Cyclically Adjusted Book per Share compare to DRMA and MBIO?
Alaunos Therapeutics' Cyclically Adjusted Book per Share of $2.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current Cyclically Adjusted Book per Share is $2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.08 — trading 205.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is $2.91. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Cyclically Adjusted Book per Share is $2.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.08 is trading 205.9% above its estimated GF Value™ of $0.68. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Cyclically Adjusted Book per Share: $2.91
  • GF Value™: $0.68 vs. price of $2.08 (205.9% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score

Get the complete analysis for TCRT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$0.68
GF Value